Researchers recently compared the initial efficacy of denosumab and zoledronate in treatment-naive patients. This study specifically addressed the critical **osteoporotic vertebral fracture risk** in individuals starting therapy. Using a large-scale TriNetX cohort, scientists evaluated fracture outcomes and mortality rates over a defined period. Their findings suggest significant differences in protective capacity between these two common injectable therapies.

Reducing Osteoporotic Vertebral Fracture Risk

The study matched over 10,000 patient pairs using propensity scores. Consequently, researchers identified that denosumab (Dmab) users faced higher fracture risks compared to those starting annual zoledronate (ZOL). Specifically, denosumab was associated with a 51% higher risk of general osteoporotic fractures. Moreover, the osteoporotic vertebral fracture risk was 60% higher for those on denosumab. Lumbar fractures showed an even more pronounced difference, with a hazard ratio of 2.225.

Impact of Dosing Intervals

Interestingly, the protective effect of denosumab appeared to decline sharply at the 6-to-7-month mark. However, protection remained stable when patients received two injections strictly within a 6-month window. This highlights the potential dangers of even minor treatment delays in clinical practice. Furthermore, subgroup analyses revealed higher risks for Dmab users who did not have diabetes or prior steroid exposure. Patients with an estimated glomerular filtration rate (eGFR) above 60 mL/min/1.73 m² also experienced less protection from denosumab compared to zoledronate.

FAQs

Why does zoledronate offer better initial protection than denosumab?

Zoledronate binds strongly to bone mineral and provides continuous antiresorptive activity over a year. In contrast, denosumab's effect wears off rapidly after six months, leading to a potential gap in protection if the next dose is slightly delayed.

Does a 1-month delay in denosumab treatment increase fracture risk?

Yes, the study indicates that even a one-month delay (dosing at 7 months instead of 6) significantly increases the risk of vertebral and lumbar fractures in treatment-naive patients.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional endorsement. Readers should not rely on this information as a substitute for consultation with a qualified healthcare professional. Refer to the latest local and national guidelines for clinical practice.

References

Lu KH et al. Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment-Naive Patients Compared With Zoledronate. Clin Pharmacol Ther. 2026 Apr 01. doi: 10.1002/cpt.70270. PMID: 41922922.

Curtis J et al. Real-world comparative effectiveness of denosumab versus zoledronic acid in postmenopausal women with osteoporosis. MDedge Osteoporosis. 2023.

Lamy O et al. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. PMC. 2023.